Cargando…

Downstream Processing of Amorphous and Co-Amorphous Olanzapine Powder Blends

The work evaluates the stability of amorphous and co-amorphous olanzapine (OLZ) in tablets manufactured by direct compression. The flowability and the compressibility of amorphous and co-amorphous OLZ with saccharin (SAC) and the properties of the tablets obtained were measured and compared to those...

Descripción completa

Detalles Bibliográficos
Autores principales: da Costa, Nuno F., Daniels, Rolf, Fernandes, Ana I., Pinto, João F.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9332588/
https://www.ncbi.nlm.nih.gov/pubmed/35893791
http://dx.doi.org/10.3390/pharmaceutics14081535
_version_ 1784758684951248896
author da Costa, Nuno F.
Daniels, Rolf
Fernandes, Ana I.
Pinto, João F.
author_facet da Costa, Nuno F.
Daniels, Rolf
Fernandes, Ana I.
Pinto, João F.
author_sort da Costa, Nuno F.
collection PubMed
description The work evaluates the stability of amorphous and co-amorphous olanzapine (OLZ) in tablets manufactured by direct compression. The flowability and the compressibility of amorphous and co-amorphous OLZ with saccharin (SAC) and the properties of the tablets obtained were measured and compared to those of tablets made with crystalline OLZ. The flowability of the amorphous and mostly of the co-amorphous OLZ powders decreased in comparison with the crystalline OLZ due to the higher cohesiveness of the former materials. The stability of the amorphous and co-amorphous OLZ prior to and after tableting was monitored by XRPD, FTIR, and NIR spectroscopies. Tablets presented long-lasting amorphous OLZ with enhanced water solubility, but the release rate of the drug decreased in comparison with tablets containing crystalline OLZ. In physical mixtures made of crystalline OLZ and SAC, an extent of amorphization of approximately 20% was accomplished through the application of compaction pressures and dwell times of 155 MPa and 5 min, respectively. The work highlighted the stability of amorphous and co-amorphous OLZ during tableting and the positive effect of compaction pressure on the formation of co-amorphous OLZ, providing an expedited amorphization technique, given that the process development-associated hurdles were overcome.
format Online
Article
Text
id pubmed-9332588
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-93325882022-07-29 Downstream Processing of Amorphous and Co-Amorphous Olanzapine Powder Blends da Costa, Nuno F. Daniels, Rolf Fernandes, Ana I. Pinto, João F. Pharmaceutics Article The work evaluates the stability of amorphous and co-amorphous olanzapine (OLZ) in tablets manufactured by direct compression. The flowability and the compressibility of amorphous and co-amorphous OLZ with saccharin (SAC) and the properties of the tablets obtained were measured and compared to those of tablets made with crystalline OLZ. The flowability of the amorphous and mostly of the co-amorphous OLZ powders decreased in comparison with the crystalline OLZ due to the higher cohesiveness of the former materials. The stability of the amorphous and co-amorphous OLZ prior to and after tableting was monitored by XRPD, FTIR, and NIR spectroscopies. Tablets presented long-lasting amorphous OLZ with enhanced water solubility, but the release rate of the drug decreased in comparison with tablets containing crystalline OLZ. In physical mixtures made of crystalline OLZ and SAC, an extent of amorphization of approximately 20% was accomplished through the application of compaction pressures and dwell times of 155 MPa and 5 min, respectively. The work highlighted the stability of amorphous and co-amorphous OLZ during tableting and the positive effect of compaction pressure on the formation of co-amorphous OLZ, providing an expedited amorphization technique, given that the process development-associated hurdles were overcome. MDPI 2022-07-23 /pmc/articles/PMC9332588/ /pubmed/35893791 http://dx.doi.org/10.3390/pharmaceutics14081535 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
da Costa, Nuno F.
Daniels, Rolf
Fernandes, Ana I.
Pinto, João F.
Downstream Processing of Amorphous and Co-Amorphous Olanzapine Powder Blends
title Downstream Processing of Amorphous and Co-Amorphous Olanzapine Powder Blends
title_full Downstream Processing of Amorphous and Co-Amorphous Olanzapine Powder Blends
title_fullStr Downstream Processing of Amorphous and Co-Amorphous Olanzapine Powder Blends
title_full_unstemmed Downstream Processing of Amorphous and Co-Amorphous Olanzapine Powder Blends
title_short Downstream Processing of Amorphous and Co-Amorphous Olanzapine Powder Blends
title_sort downstream processing of amorphous and co-amorphous olanzapine powder blends
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9332588/
https://www.ncbi.nlm.nih.gov/pubmed/35893791
http://dx.doi.org/10.3390/pharmaceutics14081535
work_keys_str_mv AT dacostanunof downstreamprocessingofamorphousandcoamorphousolanzapinepowderblends
AT danielsrolf downstreamprocessingofamorphousandcoamorphousolanzapinepowderblends
AT fernandesanai downstreamprocessingofamorphousandcoamorphousolanzapinepowderblends
AT pintojoaof downstreamprocessingofamorphousandcoamorphousolanzapinepowderblends